Publications by authors named "David Propper"

Claim this Profile
P
Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer.
Gayle S Jameson, S Danielle LeGrand, Michael S Gordon, Denise J Roe, Betsy C Wertheim, David Propper

Redox Biol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2.
Hemant M Kocher, , , , Peter Sasieni, David Propper

BMC Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical Trial.
Mikail Gögenur, Andreas Weinberger Rosen, Timothy Iveson, Rachel S Kerr, Mark P Saunders, David Propper

JAMA Surg· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer.
Corina E Antal, Tae Gyu Oh, Stefan Aigner, En-Ching Luo, Brian A Yee, David Propper

Nat Commun· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of chemotherapy on cognitive performance post-surgery in patients with colorectal cancer: A prospective cohort study.
Marie-Rose Dwek, Stanton P Newman, Stefano Brini, Pru Holder, Michael Machesney, David Propper

Psychooncology· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.
David J Propper, Fangfei Gao, Mark P Saunders, Debashis Sarker, John A Hartley

Br J Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα, and IL-1β.
Irene Olivera, Rebeca Sanz-Pamplona, Elixabet Bolaños, Inmaculada Rodriguez, Iñaki Etxeberria, David Propper

Cancer Discov· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner.
Mette Ø Agerbæk, Sara R Bang-Christensen, Ming-Hsin Yang, Thomas M Clausen, Marina A Pereira, David Propper

Nat Commun· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Harnessing cytokines and chemokines for cancer therapy.
David J Propper, Frances R Balkwill

Nat Rev Clin Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer.
Hemant M Kocher, Bristi Basu, Fieke E M Froeling, Debashis Sarker, Sarah Slater, David J Propper

Nat Commun· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
Timothy Iveson, Kathleen A Boyd, Rachel S Kerr, Jose Robles-Zurita, Mark P Saunders, David Propper

Health Technol Assess· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma.
Deepak Raj, Ming-Hsin Yang, David Rodgers, Eric N Hampton, Julfa Begum, David Propper

Gut· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.
José Robles-Zurita, Kathleen A Boyd, Andrew H Briggs, Timothy Iveson, Rachel S Kerr, David Propper

Br J Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner.
Mette Ø Agerbæk, Sara R Bang-Christensen, Ming-Hsin Yang, Thomas M Clausen, Marina A Pereira, David Propper

Nat Commun· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
Timothy J Iveson, Rachel S Kerr, Mark P Saunders, Jim Cassidy, Niels Henrik Hollander, David Propper

Lancet Oncol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma.
Natalie Cook, Bristi Basu, Donna-Michelle Smith, Aarthi Gopinathan, Jeffry Evans, David Propper

Br J Cancer· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance.
Anke Nijhuis, Hannah Thompson, Julie Adam, Alexandra Parker, Luke Gammon, David Propper

Hum Mol Genet· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
Gary Middleton, Daniel H Palmer, William Greenhalf, Paula Ghaneh, Richard Jackson, David Propper

Lancet Oncol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.
David Propper, Keith Jones, D Alan Anthoney, Wasat Mansoor, Daniel Ford

BMC Cancer· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative telomere lengths in tumor and normal mucosa are related to disease progression and chromosome instability profiles in colorectal cancer.
Nirosha Suraweera, Dmitri Mouradov, Shan Li, Robert N Jorissen, Debbie Hampson, David Propper

Oncotarget· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.
Tamas Hickish, Jim Cassidy, David Propper, Ian Chau, Stephen Falk

Eur J Cancer· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
Gary Middleton, Paul Silcocks, Trevor Cox, Juan Valle, Jonathan Wadsley, David Propper

Lancet Oncol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors.
L Rhoda Molife, Sarah M Rudman, Salma Alam, Daniel S-W Tan, Hartmut Kristeleit, David Propper

Cancer Chemother Pharmacol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53.
Anil Ghosh, Cecilia Lai, Sarah McDonald, Nirosha Suraweera, Neel Sengupta, David Propper

Exp Mol Pathol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of colorectal cancers in British Bangladeshi identifies early onset, frequent mucinous histotype and a high prevalence of RBFOX1 deletion.
Neel Sengupta, Christopher Yau, Anuratha Sakthianandeswaren, Dmitri Mouradov, Peter Gibbs, David Propper

Mol Cancer· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis